Use of an enzyme-linked immunosorbent assay that utilizes the Tc13Tul antigen of Trypanosoma cruzi to monitor patients after treatment with benznidazole

Tc13Tul antigen is expressed in the mammalian stages of Trypanosoma cruzi, the etiological agent of Chagas’ disease. Here, we designed and validated an enzyme-linked immunosorbent assay using the recombinant Tc13Tul (Tc13Tul-ELISA) and found that it had 82.5% sensitivity and 97.05% of specificity. T...

Descripción completa

Detalles Bibliográficos
Autores: Santamaría, Ana Lorena, de Rissio, Ana María, Riarte, Adelina, Garavaglia, Patricia Andrea, Bruballa, Andrea Cecilia, Rodríguez, Marcelo Adrián, Irazu, Lucía Elvira, Ruiz, Andres Mariano, Garcia, Gabriela Andrea
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2013
País:Argentina
Institución:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/24715
Acceso en línea:http://hdl.handle.net/11336/24715
Access Level:acceso abierto
Palabra clave:Chagas´ Disease
Chemotherapy
Diagnosis
Trans-Sialidase
https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
Descripción
Sumario:Tc13Tul antigen is expressed in the mammalian stages of Trypanosoma cruzi, the etiological agent of Chagas’ disease. Here, we designed and validated an enzyme-linked immunosorbent assay using the recombinant Tc13Tul (Tc13Tul-ELISA) and found that it had 82.5% sensitivity and 97.05% of specificity. To evaluate whether the decrease in antibodies against Tc13Tul may be used as an early marker of the effect of chemotherapy with benznidazole, sera from 30 T. cruzi-infected children were evaluated by Tc13Tul-ELISA before and after benznidazole treatment. While in Group A (6 months-4 years old, n = 16) the decrease of more than 30% of Tc13Tul-ELISA values showed a sensitivity similar to that of conventional serology (CS); in Group B, (5–12 years old, n = 14) the decrease of Tc13Tul-ELISA values was a better parameter than negativization of CS to monitor the impact of treatment. Therefore, the dosage of anti-Tc13Tul antibodies may be useful as a methodology complementary to CS to evaluate chagasic patients undergoing chemotherapy with benznidazole.